Innate Pharma Secures Cash & Expands Pipeline with Sobi Deal, Q2 2026 Highlights
Innate Pharma extends 2028 cash runway with Sobi partnership and €30 M raise, launching lacutamab in CTCL while diversifying with IPH4502 and monalizumab.
3 minutes to read